NEW YORK, March 4, 2013 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT) (Intercept), a clinical stage biopharmaceutical company focused on the development and commercialization of novel bile acid therapeutics to treat chronic liver diseases, today announced the appointment of Daniel P. Regan to the newly created position of Chief Commercial Officer. Mr. Regan is a seasoned commercial executive bringing more than 20 years of pharmaceutical and biotechnology industry experience to the company.
Mr. Regan joins Intercept from Inspiration Biopharmaceuticals where he served as Chief Commercial Officer. Prior to Inspiration, he held positions of increasing responsibility over a 12 year tenure at Genzyme Corporation where he led multi-functional teams in sales, marketing and commercialization, and launched several new products into both established and smaller emerging markets. In his last position, Mr. Regan served as General Manager, Senior Vice President of the U.S. Personalized Genetic Health business, where he was responsible for the U.S. rare disease franchise. Previously, Mr. Regan was the global General Manager, Senior Vice President of the Renal franchise at Genzyme, where he was responsible for the launch of Renagel and Renvela in the U.S. and internationally, as well as for the continued development and expansion of the Hectorol franchise. In addition to his domestic experience, Mr. Regan has worked extensively in the European, Latin American and Asia Pacific markets. Prior to Genzyme, he held sales and marketing positions at Janssen Pharmaceutica, a pharmaceutical division of Johnson & Johnson.
"Dan is a proven business leader with invaluable experience in commercial strategy, marketing and general management," commented Mark Pruzanski M.D., President and CEO of Intercept. "His knowledge of the evolving U.S. and European markets and his success in the global commercialization of novel therapeutics for rare orphan and more prevalent specialty indications will serve us well as we prepare for the anticipated approval and launch of OCA."
Select the service that is right for you!COMPARE ALL SERVICES
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV